We are live on ! Find out more
GILD icon

Gilead Sciences

1,522 hedge funds and large institutions have $72.7B invested in Gilead Sciences in 2018 Q2 according to their latest regulatory filings, with 76 funds opening new positions, 544 increasing their positions, 725 reducing their positions, and 107 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.04% more ownership

Funds ownership: 78.96%79% (+0.04%)

3% less funds holding

Funds holding: 1,5631,522 (-41)

6% less capital invested

Capital invested by funds: $77.5B → $72.7B (-$4.82B)

22% less funds holding in top 10

Funds holding in top 10: 6047 (-13)

25% less repeat investments, than reductions

Existing positions increased: 544 | Existing positions reduced: 725

29% less first-time investments, than exits

New positions opened: 76 | Existing positions closed: 107

31% less call options, than puts

Call options by funds: $1.25B | Put options by funds: $1.82B

Holders
1,522
Holders Change
-41
Holders Change %
-2.62%
% of All Funds
34.84%
Holding in Top 10
47
Holding in Top 10 Change
-13
Holding in Top 10 Change %
-21.67%
% of All Funds
1.08%
New
76
Increased
544
Reduced
725
Closed
107
Calls
$1.25B
Puts
$1.82B
Net Calls
-$567M
Net Calls Change
-$452M
Name Holding Trade Value Shares
Change
Change in
Stake
RMAM
1126
Raab & Moskowitz Asset Management
New Jersey
$465K -$359K -5,080 -44%
PGFC
1127
Peapack-Gladstone Financial Corp
New Jersey
$464K -$179K -2,539 -28%
THWM
1128
Taylor Hoffman Wealth Management
Virginia
$464K -$2.54K -36 -0.5%
KM
1129
Kalos Management
Georgia
$464K +$420K +5,944 New
PWMAG
1130
Pinnacle Wealth Management Advisory Group
New Jersey
$463K +$79.8K +1,130 +21%
FBT
1131
First Bankers Trust
Kentucky
$463K +$122K +1,734 +36%
QCG
1132
Quadrant Capital Group
Ohio
$460K -$27.8K -394 -5%
IEFM
1133
IQ EQ Fund Management
Ireland
$455K +$453K +6,421 New
BAM
1134
Belpointe Asset Management
Nevada
$452K +$93K +1,317 +26%
EDRIA
1135
Edmonds Duncan Registered Investment Advisors
Kansas
$451K +$7.06K +100 +2%
GWM
1136
Greenwich Wealth Management
Connecticut
$450K -$147K -2,080 -25%
HR
1137
Howe & Rusling
New York
$444K -$45.7K -647 -9%
GIA
1138
Gargoyle Investment Advisor
New Jersey
$442K -$166K -2,352 -27%
RFM
1139
Royal Fund Management
Florida
$440K -$1.52M -21,471 -78%
BTNA
1140
Bremer Trust National Association
Minnesota
$440K -$475K -6,727 -52%
IAA
1141
Independent Advisor Alliance
North Carolina
$440K -$24.7K -350 -5%
BCP
1142
Blackhawk Capital Partners
Wisconsin
$438K +$6.71K +95 +2%
FGAM
1143
Financial Gravity Asset Management
Texas
$438K +$6.78K +96 +2%
ZIC
1144
ZWJ Investment Counsel
Georgia
$437K -$15.7M -222,292 -97%
SCI
1145
S&CO Inc
Massachusetts
$437K -$113K -1,599 -21%
SC
1146
Savant Capital
Illinois
$437K -$2.9K -41 -0.7%
AWM
1147
Altium Wealth Management
New York
$437K +$104K +1,475 +31%
XS
1148
XR Securities
Illinois
$436K +$435K +6,161 New
WCM
1149
Weatherstone Capital Management
Colorado
$435K -$12.1K -172 -3%
MCP
1150
Mirador Capital Partners
California
$430K -$349K -4,943 -45%

GILD Hedge Fund Activity: Q2 2018 in Review

1,522 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q2 2018, worth a combined $72.7B — down 6.2% from $77.5B a quarter earlier.

Sellers outnumbered buyers: 107 funds closed out of GILD and 76 opened new positions — a net loss of 31 holders — while 725 trimmed existing stakes and 544 added.

The largest buyer was Capital Research Global Investors, adding an estimated $995M. The largest seller was Fidelity Investments, cutting an estimated $361M.

  • 1,522 institutional investors held Gilead Sciences (GILD) as of Q2 2018, down from 1,563 in Q1 2018.
  • Funds reported $72.7B of Gilead Sciences stock for Q2 2018, down 6.2% quarter-over-quarter.
  • 76 funds opened new Gilead Sciences positions in Q2 2018 and 107 closed out, a net change of -31 holders.
  • The largest Gilead Sciences buyer in Q2 2018 was Capital Research Global Investors, an estimated $995M added.
  • The largest Gilead Sciences seller in Q2 2018 was Fidelity Investments, an estimated $361M sold.

Based on aggregated 13F filings for Q2 2018.